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On-Command Regulation of Kinase Activity using Photonic
Stimuli
Cassandra L. Fleming,*[a] Morten Grøtli,[a] and Joakim Andréasson*[b]
The underlying role that many kinases play in complex cellular
pathways as well as disease remains unclear. To better under-
stand the role that kinases play in both health and disease
states, the use of light as an external stimulus to modulate
kinase activity with high spatiotemporal resolution has gained
increasing interest over the years. Herein we highlight the
progress made towards the development of light-responsive
kinase enzymes and small molecule inhibitors. In these exam-
ples, photolabile caging groups and photoswitchable entities
have been utilised to modulate either kinase activation or
inhibition in a light-controlled manner.
1. Introduction
Biological functions can be impeded/accelerated if a small
molecule interacts with the biomolecule of interest. This very
simple causality forms the basis for today’s rational drug design.
The ideal drug should strike the intended biomolecule(s) with
perfect selectivity, i. e., not hampering processes other than
that/those desired. Unfortunately, ideal drugs do not exist, as
the intended mechanism of action is never fully orthogonal to
all other bio-relevant processes. This results in undesired side-
effects, and is why most drug candidates never make it to the
market.
The abovementioned interactions between small molecules
and their biomolecular targets depend, of course, on the
structure of these species. So, what if one could change
dynamically the structure of the molecule using externally
controlled stimuli, to convert it to the “active” binding form
only at times and locations relevant to the therapy of interest?
This would imply an extremely good spatiotemporal precision,
and certainly decrease the side-effects. Furthermore, applying
this scheme in pre-clinical settings would also provide a
valuable research tool in which pharmacodynamical informa-
tion can be extracted.
This beguiling idea together with the use of light as the
external stimulus is today referred to as photopharmacology
and is schematically illustrated in Figure 1. Also shown is the
‘reverse’ variant of this approach, that is, cases where instead
the biomolecular targets are equipped with light responsive
units. Academic groups world-wide devote their research
efforts to this rapidly evolving cross-disciplinary field, and the
list of biorelevant systems that have been targeted include lipid
membranes,[1] enzymes,[1a,2] nucleic acids,[2a,3] ion channels and
various types of receptors.[1–2] The structural changes can be
imposed in two principally different fashions: (i) Irreversible
changes, often by the light-induced cleavage of covalent bonds
to separate the “cage” from the “bioactive” (Figure 1A and 1C).
This scheme is often referred to as uncaging or photodecaging;
(ii) Reversible structural changes using molecular photoswitches
(photochromic molecules, Figure 1B and 1D). Caging groups
come, literally, in many different colours and a selection of
these can be found in recent reviews.[4] As for the molecular
photoswitches, the azobenzene derivatives are still enjoying
clear preference, but alternatives from other photochromic
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Figure 1. Schematic depiction of photocaging and photoswitchable ap-
proaches employed in photopharmacology. (A) Irreversible light-induced
activation of enzymatic activity using caging groups; (B) Reversible photo-
control of enzymatic activity (inactive/active) using photoswitchable entities;
(C) Irreversible light-induced activation of small molecule inhibitor through
the use of a caging group; and (D) Reversible light-induced activation/
deactivation of photoswitchable small molecule inhibitor.
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families such as spiropyrans and diarylethenes are also being
frequently used in this context.[2,5]
Over the past two decades, the external control of kinase
activity using light has been explored. Protein kinases play a
fundamental role in a number of cellular functions including
cell proliferation, differentiation and apoptosis.[6] It is therefore
of no surprise that their inhibition has proven to be a valuable
therapeutic approach for the treatment of various diseases.[6]
Despite the plethora of kinase inhibitors regularly appearing in
the literature, it is evident that the majority of these inhibitors
present selectivity issues, significantly impeding their advance-
ment to a clinical setting as a result. Furthermore, the role that
many kinases play in a variety of disease states is poorly
understood. The relationship between intracellular enzymatic
activity and cellular behaviour is typically probed by the use of
genetic or siRNA-based approaches, whereby in vitro experi-
ments do not accurately reflect the real-time events or that of
the natural cellular environment, while in vivo studies often
suffer from poor spatial resolution. As such, the dynamic and
optical control of kinase activity in live cells and whole
organism settings affords an unprecedented level of spatiotem-
poral control over biological processes, adding a new layer of
experimental opportunity. This minireview serves to highlight
the progress made regarding the development of light-
responsive kinase enzymes as well as small molecule inhibitors
in which photocontrolled kinase inhibition has been the main
objective.
2. Light-Responsive Kinase Enzymes
Photoactivatable enzymes function as valuable tools to probe
the role of catalytic activity in a number of cellular pathways
with high spatiotemporal resolution. To date, optical control of
kinase function has been achieved through the site-specific
inclusion of (i) photolabile caging groups; and (ii) photosensory
domains. With the exception of one report by Lawrence and
co-workers in 2011,[7] caging moieties have been introduced
onto key amino acid residues within the catalytic active site,
masking enzymatic activity as a result (Figure 1A). Activation of
the caged kinase only occurs when exposed to a suitable
wavelength of light. Inspired by the natural photosensory light-
oxygen-voltage (LOV) domain present in algae and plants,
reversible photocontrol of kinase activity has been achieved by
the inclusion of the LOV domain into the kinase of interest.[8]
Light induced conformational changes of the LOV domain
allosterically regulates the ON/OFF catalytic activity of the
kinase (Figure 6). Examples of both photocaged and photo-
switchable kinase enzymes are presented below.
2.1. Photocaged Kinase Enzymes
Bayley and co-workers masked the catalytic activity of the
cAMP-dependent PKA through the introduction of a photo-
labile caging group onto either a cysteine (Cys199)[9] or
phosphothreonine (Thr-197)[10] residue that reside in the
‘activation loop’ of the catalytic subunit of PKA. It was
postulated that the inclusion of the 2-nitrobenzyl caging group
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(Figure 2A) on the cysteine residue disrupts the native con-
formation of the activation loop, impeding enzymatic activity
as a result. Exposure to UV light (312 nm) saw a 20–30-fold
increase in enzymatic activity.[9] The phosphorylation of the
threonine residue regulates PKA activity. The 4-hydoxyphenacyl
caging group was attached to threonine by the thiophosphor-
ylation of the residue with PKD1 in the presence of ATP(g)S,
followed by the treatment with 4-hydroxyphenacyl bromide.
The caged PKA kinase was inactive as the presence of the bulky
caging group prevents the kinase from obtaining an active
conformation. The catalytic activity of PKA was restored (to 85–
90 % of the original value) upon irradiation with UV light
(312 nm, Figure 2B).[10]
In 2011, Lawrence and co-workers reported on the develop-
ment of a photoactivatable profluorescent cAMP-dependent
kinase enzyme.[7] This was achieved through the use of an
active site-directed peptide-based ‘caging agent’ for the propin-
quity labelling of the Cys-343 nonactive site residue in the
kinase (Figure 3). The covalently modified kinase exhibited
minimal enzymatic activity (<3 % residual activity) as well as
low fluorescence due to the presence of the appended QSY7
fluorescent quencher. Upon exposure to light, the active site-
directed peptide and the appended quencher moiety was
cleaved, in turn restoring the catalytic activity of the kinase to
60–80 % of the native catalytic activity. The activation of the
cAMP-dependent kinase could be further monitored by the 10–
20-fold enhancement of the fluorescent signal that arose due
to the removal of the quencher and the simultaneous
generation of a fluorescent response. The catalytic activity of
cAMP-dependent kinases is largely responsible for the disas-
sembly of stress fibres that link the cytoskeleton of the cell with
the extracellular matrix. Using the rat embryonic fibroblast cell
line REF52, the authors demonstrated that the caged-PKA could
be used to induce the disassembly of stress fibres in a light-
dependent manner.
In efforts to realise a general approach to achieve optical
control of kinase activation, Chin and co-workers looked at the
replacement of a conserved lysine residue in the ATP binding
pocket that is critical for the phosphorylation activity of the
kinase, with a photocaged lysine derivative (5a, Figure 4), using
genetic code expansion.[11] The presence of the caging group
masked the catalytic activity of the kinase as the lysine residue
was no longer available to orientate ATP appropriately in the
catalytic domain and thus, ATP could not be accommodated for
in the binding site. The caging group was only cleaved off
when irradiated with UV light, which concurrently restored the
catalytic activity of the kinase enzyme. To date, the authors
have used this approach to create photoactivatable versions of
the MAP kinase MEK1,[11a] as well as LCK.[11b] The development of
such light-activated kinases enables the dissection of signaling
transduction pathways as well as the study of the kinetics of
the individual steps in these processes.
Deiters and co-workers[12] also employed genetic code
expansion to introduce a photocaged lysine group (5b, Fig-
ure 4) into the MEK1 active site in zebrafish embryos, and
successfully demonstrated the effects of in vivo MEK1 activation
on embryonic development. The light-induced activation of
MEK1 function at predefined time points in zebrafish embryos
revealed a time window in which the activity of the MEK/ERK
pathway is critical for dorsal/ventral patterning in developing
embryos.
2.2. Photoswitchable Kinase Enzymes
Moffat and co-workers described the development of a light-
responsive fusion kinase, YF1, by the replacement of the heme-
binding Per-Arnt-Sim sensor domain of FixL from Bradyrhi-
zobium japonicum with the photoresponsive LOV domain of
Bacillus sabtilis (YtvA, Figure 5).[13] The parent enzyme, FixL,
regulates the gene expression of proteins involved in micro-
aerobic respiration, nitrate respiration and nitrogen fixation.
This occurs via a two-step process in which FixL first undergoes
autophosphorylation. The phosphate moiety is then transferred
to FixJ, the response regulator. The in vitro phosphorylation
activity of YF1 was measured using a radioactive assay. In the
Figure 2. Optical control of PKA activity was realised by the use of
photocaged (A) cysteine and (B) phosphothreonine residues present in the
activation loop of the catalytic subunit.
Figure 3. Schematic representation of the active-site directed “caging agent”
reported by Lawrence and co-workers.[7]
Figure 4. Photocaged lysine residues 5 a and 5 b introduced into the catalytic
active site by genetic code expansion.
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dark, YF1 exhibited catalytic activity analogous to that of the
parent FixL. When exposed to white light, the phosphorylation
of FixJ was inhibited by ~1000-fold. The fusion protein YF1 also
displayed in vivo kinase activity, in which YF1 was expressed in
E. coli and its ability to regulate gene expression in a light-
dependent manner was determined using a b-galactosidase
assay.
In 2016, Dagliyan et al. demonstrated reversible optical
control of kinase activity through the inclusion of an allosteric
LOV2 photosensory domain into the Src kinase, giving rise to
OFF/ON catalytic activity that mimics the inactive/active state
of the parent kinase.[14] Irradiation of the LOV2 domain with
blue light (455 nm) results in increased flexibility and disorder
of its terminal helices. Thereby the inclusion of the LOV2
domain into the Src kinase afforded light-responsive catalytic
activity, in which the kinase activity was deactivated due to
light-induced conformational changes of the catalytic domain,
while upon returning to the dark, catalytic activity was restored
(Figure 6). The authors further demonstrated its utility in live
cells in which the light-responsive enzyme was expressed in
SYF cells that lack Src, Yes and Fyn kinases. As Src is reported to
play an important role in cell motility, irradiation of these cells
with light resulted in reduced migration rates as well as
changes in cell morphodynamics.
Employing a similar approach to that of Dagliyan et al.,
Anastasiou and co-workers inserted an allosteric photorespon-
sive LOV2 domain into the pyruvate kinase, PKM2.[15] However,
instead of toggling reversibly between distinct inactive/active
forms of the kinase, light was used to simply enhance
enzymatic activity. Exposure to blue light (460 nm) resulted in
light-induced conformational changes of protein structure
which afforded a decrease in the Michaelis constant of the
enzyme for phosphoenolpyruvate by 30 %, in turn correlating
to enhanced pyruvate kinase activity. Upon returning to the
dark state, the less active conformation of the kinase was
restored. The light-responsive PKM2 protein was expressed in
HeLa cells and incubated in media containing 13C-labelled
glucose. Irradiation with blue light resulted in a significant
increase in the labelling of pyruvate from glucose.
In 2017, Zhou et al. described the development of photo-
switchable kinases by the insertion of two photodissociable
dimeric domains into the enzyme.[16] Firstly, the dimeric domain,
pdDronpa, was engineered from the photodissociable tetramer-
ic green fluorescent protein, Dronpa145 N. Exposure to 500 nm
induced photodissociation as well as a significant decrease in
fluorescence. The fluorescent properties and photoassociation
was restored when irradiated with 400 nm. The dimeric protein
was then introduced into MEK1 at two positions that flanked
the active site. In doing so, pdDronpa prevented substrate
access, rendering the kinase inactive as a result (Figure 7). Upon
exposure to cyan light (500 nm), pdDronpa underwent photo-
dissociation and kinase activity was turned on. This approach
was also further extended to other serine/threonine kinases to
afford photoswitchable Raf1, MEK2 and CDK5 kinase enzymes.
The authors demonstrated how such photoresponsive kinase
enzymes could be used for an all-optical method for screening
kinase inhibitors, to investigate negative feedback in the Raf-
MEK-ERK pathway as well as the effects of in vivo optical
control of kinase activity on development and synaptic vesicle
transport.
3. Light-Responsive Kinase Inhibitors
The use of light-responsive kinase inhibitors is regarded as a
valuable means to probe the underlying molecular events of
complex cellular processes. Effective optical control of kinase
inhibitors has been achieved by (i) the use of photolabile
caging groups (Figure 1C); and (ii) the inclusion of photo-
chromic moieties into the molecular scaffold of the kinase
inhibitor (Figure 1D). The first approach involves the strategic
introduction of caging groups onto a region of the bioactive
that is essential for binding to the target enzyme, rendering the
inhibitor inactive. The inhibitory activity of the bioactive is only
restored upon exposure to a certain wavelength of light, in
which the caging group is cleaved off and the kinase inhibitor
is liberated in its now active form, free to bind to its
corresponding target. In the latter approach light is used to
toggle reversibly between two forms of the inhibitor, in which
one form has been designed to have a higher affinity for the
target enzyme than the other.
Figure 5. Design of light-responsive fusion protein YF1. Figure adapted with
permissions from Reference [13], copyright 2009 Elsevier.
Figure 6. Allosteric control of kinase activity by the inclusion of a LOV2
photosensory domain (blue) into the enzyme. Kinase substrate is depicted in
purple.
Figure 7. Schematic representation of photoswitchable kinases developed
by Lin and co-workers.[16] Figure adapted with premissions from Refer-
ence [16], copyright 2017 AAAS.
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3.1. Photocaged Kinase Inhibitors
While the initial report of a photocaged kinase inhibitor
appeared in the literature in 1998,[17] it was not until 2012,[18]
when the next photocaged inhibitor was published. Despite
the utility of employing light to trigger the activation of kinase
inhibitors at pre-determined time points in a biological setting,
only a handful of photocaged kinase inhibitors have been
documented in the literature.
Lawrence and co-workers reported the first caged kinase
inhibitor 7 (Figure 8), for the photocontrolled inhibition of the
cAMP-dependent kinase, PKA.[17] The 6-nitroveratryloxycarbonyl
(NVOC) caging group was introduced onto the arginine moiety
of the peptide-based kinase inhibitor 8, as it serves as an
important substrate recognition element for PKA. The caged-
inhibitor 7 functioned as a poor inhibitor of PKA (Ki = 20 mM).
Irradiation of the caged inhibitor with a Xe-arc lamp (>300 nm)
resulted in the generation of the active kinase inhibitor (Ki =
420 nM). The utility of this caged inhibitor was further
demonstrated in a rat embryo fibroblast cell line (REFs), which
when treated with a PKA activator (CPT-cAMP) underwent
pronounced morphological changes. These morphological
changes in response to the CPT-cAMP stimulus were not
observed only in the cells that were treated with the caged
inhibitor 7 and subsequently irradiated with light.
In efforts to achieve spatiotemporal inhibition of Rho kinase,
Morckel et al.[18] developed a photocaged Rho kinase inhibitor
by the installation of the 6-nitropiperonyloxymethyl (NPOM)
caging group onto a small-molecule Rho inhibitor. While no IC50
or Ki values are reported, the inhibitory activity of the caged
Rho inhibitor 9 was shown to be light-dependent (Figure 9).
When caged (compound 9), inhibition of Rho activity was not
observed. However, upon exposure to UV light (365 nm) and
the subsequent release of the Rho inhibitor in its active form
(compound 10), the catalytic activity of Rho was inhibited by
91.2 %. To further demonstrate the efficacy of the caged
inhibitor, the authors employed 9 as a probe to regulate Rho
activity in zebrafish embryos, in which Rho activity and its effect
on gut epithelial morphology was controlled in a light-depend-
ent manner.
In 2015, Bliman et al.[19] described the development of a
caged RET kinase inhibitor (11). Masking of the inhibitory
properties of the RET inhibitor 12 (previously reported by the
Grøtli group)[20] was achieved by the inclusion of a NVOC-
derived photolabile group onto the exocyclic amino moiety
that partakes in key interactions within the hinge region of the
ATP-binding site of the RET kinase (Figure 10). In a cell free
assay, 11 modestly inhibited RET with an IC50 value of 6.8 mM.
Photolysis of 11 with 365 nm afforded the active RET inhibitor
12, in which a 12-fold increase in RET inhibition was observed
(IC50 = 590 nM). Furthermore, the authors demonstrated the
utility of the photocaged inhibitor 11 as a tool to probe the
effects of spatiotemporal RET inhibition on motoneuron
development in zebrafish embryos.
Peifer and co-workers have also contributed to this field
with the development of photocaged derivatives of the FDA
approved kinase inhibitors imatinib[21] and vermurafenib[22]
(Figure 11). The inclusion of the 4,5-dimethyoxy-2-nitrobenzyl
(DMNB) caging group at the amide moiety of the benzanilide
group rendered the cage imatinib derivative 13 a poor inhibitor
of PDGFR (IC50 = 5.8 mM). The decaging reaction proceeded
upon exposure to UV light (365 nm) to release the known
inhibitor, imatinib, in its active form, with an IC50 value of
0.089 mM.[21]
The photocaged vermurafenib derivative 14 was realised
through the introduction of the same DMNB photolabile group
onto the central azaindole-NH moiety of vermurafenib, known
to partake in important interactions with the hinge region of
the ATP-binding site of the BRAF kinase.[22] A binding affinity of
440 nM was observed for the caged compound 14 for BRAF,
which is 43-fold weaker than that of vermurafenib itself (Kd =
Figure 8. Photolysis of caged inhibitor 7, affording the protein kinase
inhibitor 8 in its active form.
Figure 9. Photoactivation of Rho kinase inhibitor 10 upon irradiation of
caged derivative 9 with UV light (365 nm).
Figure 10. Photolysis of caged inhibitor 11, affording the RET inhibitor 12 in
its active form.
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10.2 nM). To demonstrate the utility of compound 14, the
melanoma cell line SkMel13 was treated with 14, in which no
antiproliferative activity was observed. Only when the treated
cells were exposed to UV light (365 nm) was the antiprolifer-
ative activity of vermurafenib restored (GI50 = 1.5 mM).
Peifer and co-workers have also described the development
of the photocaged inhibitor 15 for the receptor tyrosine kinase,
VEGFR-2 (Figure 12).[23] The inhibitor properties of the known
VEGFR-2 inhibitor 16[24] (IC50 = 0.158 mM), was masked by the
inclusion of the DMNB caging group onto the NH moiety of the
maleimide hinge binding motif (IC50 = 44.8 mM). The antiprolifer-
ative activity of 15 was evaluated on VEGFR-2 dependent PC-3
cells, in which a GI50 value of 34.6 mM was observed prior to UV
irradiation. However, upon exposure to 365 nm, the DMNB
caging group was removed and the antiproliferative properties
of 16 restored, in which a GI50 value of 0.2 mM was obtained.
In contrast to the development of caged kinase inhibitors,
in which the decaging reaction results in the release of the
inhibitor in its active form, Lawrence and co-workers describe
an alternate approach whereby light is used to trigger the
deactivation of a peptide-derived inhibitor.[25] A known bivalent
peptide-derived Src inhibitor was modified to contain a photo-
labile moiety that serves to position the peptide appropriately
for kinase inhibition. Exposure to light splits the bivalent
inhibitor, resulting in the release of the inhibitor from its
binding site as well as the restoration of the catalytic activity of
the kinase (Figure 13).
3.2. Photoswitchable Kinase Inhibitors
In 2014, Yi et al. developed photoswitchable inhibitory peptides
of cyclic-AMP dependent kinase (PKA) and MLCK (Figure 14).[26]
Known inhibitory peptide sequences of PKA and MLCK were
incorporated into the natural photosensory LOV2 domain. In
the absence of light, the inhibitor sits close to the LOV2 domain
and is unable to bind to its corresponding target due to steric
bulk. However, when exposed to blue light (460 nm), the LOV2
domain undergoes significant conformational changes and
orientates the inhibitor appropriately for binding to the kinase.
For cells expressing the photoswitchable PKA inhibitor, PKA
phosphorylation was reduced by ~50 % when exposed to blue
light. Furthermore, the PKA inhibitory peptide exhibited light-
dependent inhibition of CREB phosphorylation in live cells. The
inhibitory properties of the photoswitchable MLCK inhibitor
was also shown to be light-dependent, in which a ~70 %
decrease in MLCK activity was observed when exposed to light
(460 nm). When COS-7 cells were treated with the light-
responsive MLCK inhibitor, blue light could be used to induce
changes in cell morphodynamics.
The first example of a photoswitchable small molecule
kinase inhibitor was described by Ferreira et al. in 2015.[27] The
development of the photoswitchable RET kinase inhibitor 17
was achieved by exchanging the alkyne moiety of the known
RET inhibitor 12[20] with a photochromic azobenzene moiety
(Figure 15). Docking studies suggested that the E-form of 17
could bind to the ATP-binding site of the RET kinase in an
analogous fashion to that of 12, while the geometry of the Z-
form (17-Z) would not be accommodated for in the RET active
site, and thereby serve as a poor inhibitor of RET. Photo-
isomerisation of the E!Z form was achieved by irradiation with
Figure 11. Photoactivation of known kinase inhibitors, imatinib and vemur-
afenib, upon irradiation with UV light (365 nm).
Figure 12. Photolysis of caged inhibitor 15, affording the VEGFR-2 inhibitor
16 in its active form.
Figure 13. Schematic representation of photodeactivatable Src kinase inhib-
itor described by Lawrence and co-workers.[25]
Figure 14. Schematic representation of photoswitchable inhibitory peptide
reported by Hahn and co-workers.[26]
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365 nm light, in which a photostationary distribution of 87 % of
17-Z was obtained. The reverse reaction could also be achieved
either thermally or upon exposure to visible light (503 nm).
Furthermore, the reversible photoisomerization cycle could be
repeated 10 times without exhibiting any signs of photo-
fatigue. Cell free studies in a RET biochemical assay showed a
3.8-fold difference in inhibitory properties between the two
photo-isomers, with IC50 values of 150 nM and 580 nM for the
E-form and the photo-enriched Z-form, respectively. The
inhibitory effects of the photoswitchable RET inhibitor 17 was
also demonstrated in a whole cell functional assay, in which IC50
values for the active E-form and the inactive Z-form of 3.8 mM
and 12 mM, respectively, were obtained.
Recognising the structural similarities between the known
bisindolylmaleimide (BIM) family of ATP kinase inhibitors (18)
and the photochromic diarylmaleimide moiety, Branda and co-
workers describe the development of a photochromic PKC
inhibitor in which the photochromic diarylmaleimide moiety
has been incorporated into the pharmacophore of a BIM-
derived kinase inhibitor (Figure 16).[28] The s-trans-s-trans con-
formation of the open form (19-i) can be readily accommo-
dated for in the ATP-binding site of PKC, thus serving as the
active form. However, in order to photoisomerise to the inactive
closed form (19-C), 19-i must reorientate to adopt a s-cis-s-cis
conformation (19-O). Unfortunately, the photoinduced ring-
closing reaction of diarylmaleimide derivatives is highly de-
pendent on the polarity of the solvent system, and cannot
occur in highly polar environments.[29] This is largely due to the
presence of a twisted intramolecular charge transfer state that
is populated upon photoexcitation and surpasses that of the
ring-closing reaction.[29] As the photocyclisation reaction is
suppressed in aqueous medium, reversible photoisomerisation
between the open and closed form of 19 had to be conducted
in organic solvent. Nevertheless, the authors were able to
demonstrate that the in vitro activation of 19 could be readily
achieved when an isolated sample of 19-C was irradiated with
490 nm to afford the active open form, 19-i, which inhibited
PKC with an IC50 of 580 nM.
In efforts to achieve both isoform selective and optically
controlled MEK inhibition, Chin and co-workers employed a
bioorthogonal ligand tethering (BOLT) approach, in which the
MEK1/2 inhibitor 20 is covalently attached to a modified amino
acid residue on the protein surface of MEK1 through a
photoswitchable linker (compound 22, Figure 17).[30] When in
the trans-form, the allosteric inhibitor should be able to bind to
the kinase, thus preventing phosphorylation, while in the cis-
form, the inhibitor is no longer positioned appropriately to
bind to MEK1, restoring the catalytic activity as a result.
Reversible optical control of MEK1 catalytic activity in live
HEK293ET cells was observed, in which 360 and 440 nm was
used to toggle between the cis/trans-isomers.
Figure 15. Photoswitchable RET inhibitor 17 derived from known RET
inhibitor 12.
Figure 16. Photochromic PKC inhibitor 19 derived from the known PKC
inhibitor 18.
Figure 17. Optical control of MEK1 activity using a photoswitchable BOLT
approach. (A) The MEK1/2 inhibitor (green) is conjugated to a reactive group
(blue) via a photoswitchable linker (red). Following incubation with the
ligand (compound 22), the target kinase is inhibited. Upon exposure to
360 nm, the linker isomerises from the trans- to the cis-form, resulting in the
activation of the kinase; (B). MEK1/2 inhibitor 22. Unnatural amino acid 21
introduced onto the protein surface of MEK1. The inhibitor is conjugated to
the reactive group via an azobenzene linker 22. Figure (A) adapted with
permissions from Reference [30], copyright 2015 Nature Publishing Group.
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Most recently, Schmidt et al. investigated the photoinduced
isomerisation of the known VEGFR2 kinase inhibitor, Axitinib
(23-E), which consists of the photoresponsive stilbene moiety
that should allow for reversible E/Z-isomerisation (Figure 18).[31]
As molecular modelling studies showed that in the Z-isomer
(23-Z) is unable to participate in critical interactions with the
hinge region of the active site and therefore should function as
a poor inhibitor of VEGFR2, it was envisioned that photo-
induced isomerisation could be employed to regulate the
inhibitory activity of Axitinib ‘OFF’ and ‘ON’. While reversible
switching was readily demonstrated in DMSO, unfortunately
E!Z photoisomerisation in aqueous solution was not realised
as a competing irreversible [2 + 2]-photocycloaddition reaction
to afford the inactive Axitinib dimer 24 was observed. The
authors demonstrated optical control of Axitinib in a VEGFR2
kinase assay. In the absence of light, 23-Z exhibited an IC50
value of 817 nM. Upon exposure to 385 nm light, 23-Z was
photoisomerised to the corresponding active form, 23-E, in
which an IC50 value of 29 nM was obtained. When these
experiments were repeated in a HUVEC proliferation assay, 23-Z
exhibited an IC50 value of 26 mM. However, after the light-
induced Z!E isomerisation (385 nm), the inhibitory activity was
found to increase by only a factor of 2.6 (23-E IC50 = 10 mM),
suggesting that the Z!E photoisomerisation was not as
efficient in a cellular context.
4. Summary and Outlook
Light serves as a valuable external stimulus to probe bio-
relevant mechanisms as it is non-invasive, can be delivered with
high spatiotemporal resolution and is readily controlled by
simply adjusting the wavelength and intensity. To date, much
effort has been devoted to the development of valuable light-
responsive tools to study complex cellular pathways. The role
of many kinases in signal transduction pathways and various
diseases is poorly understood. In this minireview, we highlight
the progress made towards the development of light-respon-
sive kinase enzymes and small molecule inhibitors to probe the
role of kinases in both health and disease states.
Photolabile caging moieties have been strategically intro-
duced onto (i) kinase enzymes to mask their catalytic activity;
and (ii) small molecule kinase inhibitors to prevent them from
binding to their corresponding target. Catalytic activity or the
ability to bind to the target is only restored when exposed to
light. To date, all examples employ the use of UV light to initiate
the decaging reaction, therefore impeding their utility in more
advanced animal model systems. The toxicity of UV light
towards biological samples is well established, in which
extensive exposure may result in mutations and induce cell
apoptosis.[32] Furthermore, UV light exhibits poor tissue pene-
tration in which depths of only a few millimetres can be
reached.[33] To the best of our knowledge, photocaged kinase
enzymes and inhibitors that employ longer wavelengths have
yet to be reported. As such, we should turn our focus to
employing caging groups that utilise longer wavelengths, as
well as the use of two photon methods.
Unfortunately, the use of caging groups does not allow for
reversible optical control over kinase activation/inhibition. The
activation of either the kinase itself or the small molecule
inhibitor can only occur at a single predefined time point. The
use of photoswitchable entities enables one to obtain dynamic
and reversible control over both kinase activation and inhib-
ition, however, other critical parameters have to be considered
when photoswitches are employed. These include:
(a) The ratio of the two photoisomers at the photostationary
state. The OFF/ON changes in catalytic activity directly
correlate to the percentage of the sample that undergoes
photoisomerisation to the respective isomeric form. Ideally,
a quantitative conversion from one form to the other
occurs when exposed to light. However, this is often not
the case due to spectral overlap of the two forms.
(b) The thermal stability of the photo-enriched isomer follow-
ing irradiation. Preferably, the photo-enriched species is
stable in the dark until photoisomerisation to the respec-
tive isomer occurs.
(c) The photostability of the photoswitch should be good
enough to allow for repeated toggling between the two
forms without the occurrence of photodecomposition.
Photoswitchable kinases that exhibit OFF/ON catalytic
activity that mimics that of the parent enzyme have been
achieved by either the inclusion of an allosteric LOV2 photo-
sensory domain or the insertion of a photodissociable dimeric
domain into the kinase of interest. It is also worth noting that
all examples employ longer wavelengths (400–500 nm) for
isomerisation compared to the UV light used for the decaging
reactions.
Due to the challenges regarding the design and synthesis
of photoswitchable kinase inhibitors in which significant differ-
Figure 18. Photoinduced isomerisation of known VEGFR2 inhibitor Axitinib
(23-Z!23-E) upon exposure to 385 nm, as well as the [2 + 2] photo-
cycloaddition of 23-E to 24 when irradiated with light of wavelength
365 nm.
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ences in the affinity for the target between the active and
inactive form is achieved, only a handful of examples have
been reported. In order to achieve distinct OFF/ON switching of
kinase activity, the difference in the affinity for the target
between the active and inactive form should be significant (>
100-fold). To date, only a modest difference in kinase activity
between the two forms has been observed.
As the field of photopharmacology continues to rapidly
evolve, so does the possibilty to move past the simple ‘Proof-of-
Concept’ phase into the next stage in which these light-
responsive tools can be applied in advanced pre-clinical
biological systems. The ability to selectively probe the relation-
ship between kinase activity and cellular behaviour, with high
spatiotemporal resolution, will further our understanding of the
role that kinases play in cell signalling pathways, and may even
give rise to the identification of new therapeutic targets.
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